| Regalcare At Greenwich | |
| 1188 King Street, Greenwich, Connecticut 06831 | |
| (203) 531-8300 | |
| Name | Regalcare At Greenwich |
|---|---|
| Location | 1188 King Street, Greenwich, Connecticut |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 75 |
| Occupancy Rate | 63.6% |
| Medicare ID (CCN) | 075069 |
| Legal Business Name | Fairview Health Of Greenwich Llc |
| Ownership Type | For Profit - Limited Liability Company |
| NPI Number | 1023198470 |
| Organization Name | FAIRVIEW HEALTH OF GREENWICH LLC |
| Address | 1188 King Street, Greenwich, CT 06830 |
| Phone Number | 203-531-8300 |
News Archive
Most new mothers in the United States begin breastfeeding when their children are born, but new research shows that those who report early concerns or problems with breastfeeding are nearly 10 times more likely to abandon breastfeeding within two months.
After almost a year and a half of the COVID-19 pandemic, the actual case count of those infected with its causative virus – SARS-CoV-2 – remains unclear. Though well over 167.2 million cases have been reported worldwide, this is certainly believed by many to be a massive undercount. A new epidemiological study uses the classical SIR-C mathematical model to find the peak size and date of cases, both documented and unidentified, and the gap between them.
In just three months, demand for lab and office space at the Johns Hopkins innovation hub, FastForward East, has exceeded supply. The FastForward program, designed to move academic findings through translational research into the commercial marketplace, was introduced to East Baltimore earlier this year in an interim facility in the Rangos Building at 855 N. Wolfe St. In that time, all of its offices and lab benches have been rented.
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease.
Covalon Technologies Ltd. (the "Company" or "Covalon"), an advanced medical technologies company, today announced that further to its press release of August 16, 2013, it has completed, subject to final approval of the TSX Venture Exchange, a non-brokered private placement comprised of 750 units (the "Units") at a price of $1,000 per Unit for gross proceeds of $750,000. Each Unit consists of $1,000 principal amount of 12% senior secured convertible debenture (the "Debentures" and each a "Debenture") and 6,451 warrants (each, a "Warrant").
› Verified 7 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Most new mothers in the United States begin breastfeeding when their children are born, but new research shows that those who report early concerns or problems with breastfeeding are nearly 10 times more likely to abandon breastfeeding within two months.
After almost a year and a half of the COVID-19 pandemic, the actual case count of those infected with its causative virus – SARS-CoV-2 – remains unclear. Though well over 167.2 million cases have been reported worldwide, this is certainly believed by many to be a massive undercount. A new epidemiological study uses the classical SIR-C mathematical model to find the peak size and date of cases, both documented and unidentified, and the gap between them.
In just three months, demand for lab and office space at the Johns Hopkins innovation hub, FastForward East, has exceeded supply. The FastForward program, designed to move academic findings through translational research into the commercial marketplace, was introduced to East Baltimore earlier this year in an interim facility in the Rangos Building at 855 N. Wolfe St. In that time, all of its offices and lab benches have been rented.
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease.
Covalon Technologies Ltd. (the "Company" or "Covalon"), an advanced medical technologies company, today announced that further to its press release of August 16, 2013, it has completed, subject to final approval of the TSX Venture Exchange, a non-brokered private placement comprised of 750 units (the "Units") at a price of $1,000 per Unit for gross proceeds of $750,000. Each Unit consists of $1,000 principal amount of 12% senior secured convertible debenture (the "Debentures" and each a "Debenture") and 6,451 warrants (each, a "Warrant").
› Verified 7 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 2 |
| Total Amount of Fines in Dollars | $29250 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 2 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 29.33 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 7.39 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 26.6 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.4 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.13 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 4.05 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.39 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 77.54 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 22.36 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 19.74 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 5 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 24.81 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 13.62 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 10.71 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 96.46 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 72.7 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 43.64 | 82.93 |
News Archive
Most new mothers in the United States begin breastfeeding when their children are born, but new research shows that those who report early concerns or problems with breastfeeding are nearly 10 times more likely to abandon breastfeeding within two months.
After almost a year and a half of the COVID-19 pandemic, the actual case count of those infected with its causative virus – SARS-CoV-2 – remains unclear. Though well over 167.2 million cases have been reported worldwide, this is certainly believed by many to be a massive undercount. A new epidemiological study uses the classical SIR-C mathematical model to find the peak size and date of cases, both documented and unidentified, and the gap between them.
In just three months, demand for lab and office space at the Johns Hopkins innovation hub, FastForward East, has exceeded supply. The FastForward program, designed to move academic findings through translational research into the commercial marketplace, was introduced to East Baltimore earlier this year in an interim facility in the Rangos Building at 855 N. Wolfe St. In that time, all of its offices and lab benches have been rented.
Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the initiation of ITI-007-200, a Phase I/II clinical trial designed to evaluate the safety, tolerability and pharmacokinetics of low doses of its lead drug candidate, ITI-007, in healthy geriatric subjects and in patients with dementia, including Alzheimer's disease.
Covalon Technologies Ltd. (the "Company" or "Covalon"), an advanced medical technologies company, today announced that further to its press release of August 16, 2013, it has completed, subject to final approval of the TSX Venture Exchange, a non-brokered private placement comprised of 750 units (the "Units") at a price of $1,000 per Unit for gross proceeds of $750,000. Each Unit consists of $1,000 principal amount of 12% senior secured convertible debenture (the "Debentures" and each a "Debenture") and 6,451 warrants (each, a "Warrant").
› Verified 7 days ago
Greenwich Woods Rehabilitation Location: 1165 King Street, Greenwich, Connecticut 06831 Phone: (203) 531-1335 |